TY - JOUR
T1 - In utero exposure to breast cancer treatment
T2 - a population-based perinatal outcome study
AU - Safi, Nadom
AU - Anazodo, Antoinette
AU - Dickinson, Jan E.
AU - Lui, Kei
AU - Wang, Alex Y.
AU - Li, Zhuoyang
AU - Sullivan, Elizabeth A.
PY - 2019/10/15
Y1 - 2019/10/15
N2 - Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. We conducted a prospective cohort study to examine the perinatal outcomes of babies born following in utero exposure to chemotherapy in Australia and New Zealand. Over 18 months we identified 24 births, of >400 g and/or >20-weeks' gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.
AB - Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. We conducted a prospective cohort study to examine the perinatal outcomes of babies born following in utero exposure to chemotherapy in Australia and New Zealand. Over 18 months we identified 24 births, of >400 g and/or >20-weeks' gestation, to women diagnosed with breast cancer in the first or second trimesters. Eighteen babies were exposed in utero to chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our findings show that breast cancer diagnosed during mid-pregnancy is often treated with chemotherapy. Other than induced preterm births, there were no serious adverse perinatal outcomes.
U2 - 10.1038/s41416-019-0563-x
DO - 10.1038/s41416-019-0563-x
M3 - Editorial
C2 - 31488880
SN - 0007-0920
VL - 121
SP - 719
EP - 721
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 8
ER -